Phase 2 N=10 Omalizumab in Severe and Refractory Solar Urticaria
Solar Urticaria
Primary: Proportion of Patients With Remission of Solar Urticaria Under Experimental Conditions (Phototesting) — 2 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=67 Rapid Antidepressant Effects of Ketamine in Major Depression
Depression · Mood Disorders · Major Depresssion
Primary: MADRS Score - Baseline — 1.17; 1.48; 33.83; 31.82 units on a scale
N/A N=115 Efficacy of Ear Neurostimulation for Adolescents With Functional Abdominal Pain
Functional Disorder of Intestine · Nausea Persistent
Primary: Pain Frequency-Severity-Duration Scale (PFSD) Score — 5.0; 7.0 units on a scale — p=0.003
Phase 2 N=66 Oxytocin for Couples Conflict Resolution
Substance Misuse · Interpersonal Conflict · Neuroendocrine Reactivity
Primary: Change in Frequency of Distress Maintaining Attributions — .81; -.48 distress maintaining attributions
Phase 3 N=127 Multicenter Trial of Combined Pharmacotherapy to Treat Cocaine Dependence
Cocaine Dependence
Primary: Three Weeks of Cocaine Abstinence at End of Study — 9; 0 Participants
Phase 1 N=23 A Study Of 4-1BB Agonist PF-05082566 Plus PD-1 Inhibitor MK-3475 In Patients With Solid Tumors (B1641003/KEYNOTE-0036)
Advanced Solid Tumors
Primary: Number of Participants With Dose-Limiting Toxicities (DLT) of PF-05082566 in Combination With MK-3475 — 0; 0; 0; 0 Participants
Phase 1 N=13 Safety Study of Sirolimus and Hydroxychloroquine in Women With Lymphangioleiomyomatosis
Lymphangioleiomyomatosis
Primary: Safety of Combination Therapy With Sirolimus and Hydroxychloroquine in LAM Patients — 2.27; 1.11; 0; 1.11 Percentage of adverse events
N/A N=56 Transversus Abdominal Plane Block at Total Laparoscopic Hysterectomy: Effect on Quality of Recovery
Pain, Postoperative · Anesthesia
Primary: Quality of Recovery Questionnaire (QoR-40) on Postop Day #1 or #2 — 168.0; 169.5 units on a scale
Phase 1 N=162 Pharmacokinetics and Safety of BI 695501
Healthy
Primary: Area Under the Concentration-time Curve of BI 695501 in Plasma Over the Time Interval From 0 to 1368 Hours (AUC0-1368) After Administration Via PFS and AI. — 2100; 2150…
N/A N=9 Immunotherapy for the Treatment of Breast Cancer Related Upper Extremity Lymphedema (BCRL)
Breast Cancer · Upper Extremity Lymphedema
Primary: Volume Changes as Measured by Perometry
N/A N=128 A Study For Using Radiosurgery On Limited Metastases
Neoplasms, Metastatic
Primary: Percentage of Curatively Treated Patients With Progression-free Survival — 16 percentage of participants
N/A N=84 Urinary Retention After Total Laparoscopic Hysterectomy With Immediate Foley Catheter Removal Versus Backfill Void Trial
Urinary Retention · Voiding Disorders
Primary: Number of Participants With Void Trial Failure Rate — 7; 11 Participants
Phase 4 N=103 Immune and Hormone Response to Influenza Vaccine
Healthy
Primary: Change in Levels of Progesterone After Influenza Vaccination — 0.62; 0.43; 0.73; 0.59 ng/ml
Phase 3 N=9 Darbepoetin Alfa MDS Companion Protocol
Myelodysplastic Syndrome (MDS)
Primary: Number of Participants With Treatment-emergent Adverse Events — 9; 8; 2; 0 Participants
Phase 2 N=42 Phase II Trial of Alisertib With Induction Chemotherapy in High-risk AML
Acute Myeloid Leukemia
Primary: Number of Participants That Achieved Complete Remission — 20 Participants